Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease (SUVN-502)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03564964|
Expanded Access Status : Available
First Posted : June 21, 2018
Last Update Posted : September 24, 2019
|First Submitted Date||May 28, 2018|
|First Posted Date||June 21, 2018|
|Last Update Posted Date||September 24, 2019|
|Brief Title||Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease|
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to SUVN-502 for the treatment of Alzheimer's Disease. Investigator as well as the subject/caregiver must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the patient's medical history and program eligibility criteria.
Subjects will not be evaluated for efficacy and safety during the expanded access.
|Detailed Description||Not Provided|
|Study Type||Expanded Access|
|Expanded Access Type||Intermediate-size Population|
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Expanded Access Status||Available|
|Listed Location Countries||Not Provided|
|Removed Location Countries|
|Responsible Party||Suven Life Sciences Limited|
|Study Sponsor||Suven Life Sciences Limited|
|PRS Account||Suven Life Sciences Limited|
|Verification Date||September 2019|